Erratum to: History of narcolepsy at Stanford University. [Immunol Res, (2014) 58, (315-339) DOI 10.1007/s12026-014-8513-4];History of narcolepsy at Stanford University

Immunologic Research

Volumn 58, Issue 2-3, 2014, Pages 315-339

  Mignot, Emmanuel J M ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Autoimmune disease; Cataplexy; DQB1 z.ast; 06:02; HLA; MHC; Narcolepsy

Indexed keywords

ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; HLA DQ ANTIGEN; HLA DR2 ANTIGEN; INFLUENZA VACCINE; MODAFINIL; OREXIN; OREXIN 2 RECEPTOR; OREXIN A; HISTOCOMPATIBILITY ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

2009 H1N1 INFLUENZA; CATAPLEXY; CD4+ T LYMPHOCYTE; CELL KILLING; CEREBROSPINAL FLUID; DOPAMINERGIC TRANSMISSION; ETHNIC GROUP; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HLA SYSTEM; HUMAN; IMMUNOLOGICAL TOLERANCE; MOLECULAR MIMICRY; NARCOLEPSY; NERVE CELL; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REM SLEEP; REVIEW; UPPER RESPIRATORY TRACT INFECTION; WAKEFULNESS; ALLELE; ANIMAL; COMPLICATION; DISEASE MODEL; DOG; GENETIC PREDISPOSITION; GENETICS; HISTORY; IMMUNOLOGY; MEDICAL SCHOOL; METABOLISM; MICROBIOLOGY; PATHOPHYSIOLOGY; RESEARCH; RESPIRATORY TRACT INFECTION; TRENDS; UNITED STATES; UNIVERSITY; VIROLOGY;

ALLELES; ANIMALS; CALIFORNIA; DISEASE MODELS, ANIMAL; DOGS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HISTOCOMPATIBILITY ANTIGENS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNE TOLERANCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR MIMICRY; NARCOLEPSY; NEUROPEPTIDES; PREVALENCE; RECEPTORS, ANTIGEN, T-CELL; RESEARCH; RESPIRATORY TRACT INFECTIONS; SCHOOLS, MEDICAL; SLEEP, REM; UNIVERSITIES;

EID: 84901436269     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-015-8656-y     Document Type: Erratum

References (218)

1. Schenck CH, Bassetti CL, Arnulf I, Mignot E. English translations of the first clinical reports on narcolepsy and cataplexy by Westphal and Gelineau in the late 19th century, with commentary. J Clin Sleep Med. 2007;3(3):301-11.
2. Westphal C. Eigenthümliche mit Einschläfen verbundene Anfälle. Arch Psychiat. 1877;7:631-5.
3. Gélineau JBE. De la narcolepsie. Gazette des hôpitaux. 1880;53:626-8.
4. Yoss RE, Daly DD. Narcolepsy. Med Clin N Am. 1960;44:953-68.
5. Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. 2012;9(4):739-52. doi:10.1007/s13311-012-0150-9.
6. Plazzi G, Serra L, Ferri R. Nocturnal aspects of narcolepsy with cataplexy. Sleep Med Rev. 2008;12(2):109-28. doi:10.1016/j.smrv.2007.08.010.
7. Daniels L. Narcolepsy. Medicine. 1934;13(1):1-122.
8. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59(10):1553-62.
9. Von Economo C. Encephalitis Lethargica. London: Oxford Medical Publications, Humphrey Milford, Oxford University Press; 1931.
10. Taubenberger JK, Baltimore D, Doherty PC, Markel H, Morens DM, Webster RG et al. Reconstruction of the 1918 influenza virus: unexpected rewards from the past. MBio. 2012;3(5). doi:10.1128/mBio.00201-12.
11. Ravenholt RT, Foege WH. 1918 influenza, encephalitis lethargica, parkinsonism. Lancet. 1982;2(8303):860-4. (Pubitemid 12018557)
12. Dourmashkin RR, Dunn G, Castano V, McCall SA. Evidence for an enterovirus as the cause of encephalitis lethargica. BMC Infect Dis. 2012;12:136. doi:10.1186/1471-2334-12-136.
13. Mignot E. Why we sleep: the temporal organization of recovery. PLoS Biol. 2008;6(4):e106. doi:10.1371/journal.pbio.0060106.
14. Symonds CP, Oxf MD, Lond FRCP. Narcolepsy as a symptom of encephalitis lethargica. Lancet. 1922;173:1214-5.
15. Aldrich MS, Naylor MW. Narcolepsy associated with lesions of the diencephalon. Neurology. 1989;39(11):1505-8. (Pubitemid 19286011)
16. Aserinski E, Kleitman N. Regularly occurring periods of eye motility, and concomitant phenomena, during sleep. Science. 1953;118:273-4.
17. Jouvet M. Recherche sur les structures nerveuses et les mecanismes responsables des differentes phases du sommeil physiologique. Arch Ital Biol. 1962;100:125-206.
18. Dement W, Wolpert EA. The relation of eye movement, body motility, and external stimuli to dream content. J Exp Psychol. 1958;55:543-53.
19. Rechtschaffen A, Wolpert EA, Dement WC, Mitchell SA, Fisher C. Noctural sleep of narcoleptics. Electroencephalogr Clin Neurophysiol. 1963;15:599-609.
20. Rechschaffen A, Dement W. Studies on the relation of narcolepsy, cataplexy and sleep with low voltage random EEG activity. In: Kety S, Evarts E, Williams H, editors. Sleep and altered states of consciousness. Baltimore: Williams and Wilkins; 1967. p. 488-505.
21. Vogel G. Studies in psychophysiology of dreams III. The dream of narcolepsy. Arch Gen Psychiatry. 1960;3:421-8.
22. Andlauer O, Moore IV H, Jouhier L, Drake C, Peppard PE, Han F et al. Nocturnal REM sleep latency for identifying patients with narcolepsy/hypocretin deficiency. JAMA Neurol. 2013;70(7):891-902.
23. Dement WC. A personal history of sleep disorders medicine. J Clin Neurophysiol. 1990;7(1):17-47. (Pubitemid 20097605)
24. Dement WC. The history of narcolepsy and other sleep disorders. J Hist Neurosci. 1993;2(2):121-34. doi:10.1080/09647049309525558.
25. Dement WC, Carskadon M, Ley R. The prevalence of narcolepsy II. Sleep Res. 1973;2:147.
26. Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a populationbased study. Sleep. 2002;25(2):197-202. (Pubitemid 34193581)
27. Ohayon MM, Priest RG, Zulley J, Smirne S, Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology. 2002;58(12):1826-33. (Pubitemid 34663586)
28. Pelayo R, Hodgson N, Guilleminault C. The history of sleep medicine. Handb Clin Neurol. 2010;95:547-56. doi:10.1016/S0072-9752(08)02134-9.
29. Shepard JW Jr, Buysse DJ, Chesson AL Jr, Dement WC, Goldberg R, Guilleminault C, et al. History of the development of sleep medicine in the United States. J Clin Sleep Med. 2005;1(1):61-82.
30. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep. 1986;9(4):519-24. (Pubitemid 17131209)
31. Richardson GS, Carskadon MA, Flagg W, Van den Hoed J, Dement WC, Mitler MM. Excessive daytime sleepiness in man: multiple sleep latency measurement in narcoleptic and control subjects. Electroencephalogr Clin Neurophysiol. 1978;45(5):621-7. (Pubitemid 9031575)
32. Mitler MM, Van den Hoed J, Carskadon MA, Richardson G, Park R, Guilleminault C, et al. REM sleep episodes during the multiple sleep latency test in narcoleptic patients. Electroencephalogr Clin Neurophysiol. 1979;46(4):479-81. (Pubitemid 9126960)
33. Honda Y. Introduction to "HLA in narcolepsy". In: Honda Y, Juji T, editors. HLA in narcolepsy. New York: Springer; 1988. p. 1-10.
34. Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens. 1984;24(5):316-9. (Pubitemid 15199473)
35. Honda Y. Clinical features of narcolepsy: Japanese experience. In: Honda Y, Juji T, editors. HLA in narcolepsy. New York: Sringer; 1988. p. 24-57.
36. Billiard M, Seignalet J. Extraordinary association between HLA-DR2 and narcolepsy. Lancet. 1985;1:226-7. (Pubitemid 15151497)
37. Mueller-Eckhardt G, Meier-Ewert K, Schendel DJ, Reinecker FB, Multhoff G, Mueller-Eckhardt C. HLA and narcolepsy in a German population. Tissue Antigens. 1986;28(3):163-9. (Pubitemid 16008476)
38. Montplaisir J, Poirier G. HLA in narcolepsy in Canada. In: Honda Y, Juji T, editors. HLA in narcolepsy. New York: Springer; 1988. p. 97-107.
39. Roth B, Nevsimalova S, Sonka K, Docekal P, Schulz H, Geisler P, et al. A study of occurrence of HLA DR2 in 124 narcoleptics: clinical aspects. Arch Suiss Neurol et de Psychiat. 1988;139(4):41-51.
40. Guilleminault C, Holloman J, Grumet C, Kilduff T, McDevitt HO, Dement WC, et al. HLA-DR2 and the narcolepsy syndrome: the Stanford experience. In: Honda Y, Juji T, editors. HLA in narcolepsy. New York: Springer; 1988. p. 108-113.
41. Guilleminault C, Grumet C. HLA-DR2 and narcolepsy: not all narcoleptic-cataplectic patients are DR2. Hum Immunol. 1986;17(1):1-2. (Pubitemid 16042325)
42. Matsuki K, Honda Y, Juji T. Diagnostic criteria for narcolepsy and HLA-DR2 frequencies. Tissue Antigens. 1987;30(4):155-60. (Pubitemid 17160904)
43. Marcadet A, Gebuhrer L, Betuel H, Seignalet J, Freidel AC, Confavreux C, et al. DNA polymorphism related to HLA-DR2 Dw2 in patients with Narcolepsy. Immunogenetics. 1985;22:679-83. (Pubitemid 16232331)
44. Naohara T, Honda Y, Juji T. Positive HLA-Dw2 in Narcolepsy. In: Honda Y, Juji T, editors. HLA in narcolepsy. New York: Springer; 1988. p. 121-9.
45. Uryu N, Maeda M, Nagata Y, Matsuki K, Juji T, Honda Y, et al. No difference in the nucleotide sequence of the DQ beta beta 1 domain between narcoleptic and healthy individuals with DR2, Dw2. Hum Immunol. 1989;24(3):175-81. (Pubitemid 19072835)
46. Holloman JD, Bell JI, Kilduff TS, Dement WC, Guilleminault C. HLA-DR restriction-fragment-length polymorphisms in narcolepsy. J Neurosci Res. 1987;18:239-44.
47. Inoko H. DNA typing in Narcolepsy. In: Honda Y, Juji T, editors. HLA in narcolepsy. New York: Springer; 1988. p. 137-49.
48. Serjeantson SW, Gao X, Hawkins BR, Higgins DA, Yu YL. Novel HLA-DR2-related haplotypes in Hong Kong Chinese implicate the DQB1&z.ast;0602 allele in susceptibility to multiple sclerosis. Eur J Immunogenet. 1992;19(1-2):11-9.
49. McDevitt HO, Tyan ML. Genetic control of the antibody response in inbred mice. Transfer of response by spleen cells and linkage to the major histocompatibility (H-2) locus. J Exp Med. 1968;128(1):1-11.
50. Dausset J. Correlation between histocompatibility antigens and susceptibility to illness. Prog Clin Immunol. 1972;1:183-210.
51. Matsuki K, Juji T, Honda Y. Immunological features of narcolepsy in Japan. In: Honda Y, Juji T, editors. HLA in narcolepsy. New York: Springer; 1988. p. 150-7.
52. Rubin RL, Hajdukovich RM, Mitler MM. HLA DR2 association with excessive somnolence in narcolepsy does not generatize to sleep apnea and is not accompanied by systemic autoimmune abnormalities. Clin Immunol Immunipathol. 1988;49:149-58.
53. Mignot E, Guilleminault C, Grumet FC, Dement WC. Is narcolepsy an autoimmune disease? In: Smirne S, Francesci M, Ferini-Strambi L, Zucconi M, editors. Proceedings of the third Milano international symposium, "sleep, hormones, and the immune system", Sept 18-19. Milan: Masson; 1992. p. 29-38.
54. Carlander B, Eliaou JF, Billiard M. Autoimmune hypothesis in narcolepsy. Neurophysiol Clin. 1993;23:15-22. (Pubitemid 23051848)
55. Ellis MC, Hetisimer AH, Ruddy DA, Hansen SL, Kronmal GS, McClelland E, et al. HLA class II haplotype and sequence analysis support a role for DQ in narcolepsy. Immunogenetics. 1997;46(5):410-7. (Pubitemid 27388992)
56. Matsuki K, Grumet FC, Lin X, Gelb M, Guilleminault C, Dement WC, et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet. 1992;339(8800):1052.
57. Mignot E, Kimura A, Lattermann A, Lin X, Yasunaga S, Mueller-Eckhardt G, et al. Extensive HLA class II studies in 58 non-DRB1&z.ast;15 (DR2) narcoleptic patients with cataplexy. Tissue Antigens. 1997;49(4):329-41. (Pubitemid 27174284)
58. Kadotani H, Faraco J, Mignot E. Genetic studies in the sleep disorder narcolepsy. Genome Res. 1998;8(5):427-34. (Pubitemid 28256793)
59. Lock CB, Welsh KI, Parkes JD, Briggs DC, Waughan RW, Van Dam M. HLA in narcolepsy-cataplexy in the United Kingdom. In: Honda Y, Juji T, editors. HLA in narcolepsy. New York: Springer; 1988. p. 76-88.
60. Mignot E, Lin X, Arrigoni J, Macaubas C, Olive F, Hallmayer J, et al. DQB1&z.ast;0602 and DQA1&z.ast;0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep. 1994;17(8 Suppl):S60-7.
61. Mitler MM, Boysen BG, Campbell L, Dement WC. Narcolepsy- cataplexy in a female dog. Exp Neurol. 1974;45(2):332-40.
62. Baker TL, Foutz AS, McNerney V, Mitler MM, Dement WC. Canine model of narcolepsy: genetic and developmental determinants. Exp Neurol. 1982;75(3):729-42. (Pubitemid 12185597)
63. Foutz A, Mitler M, Cavalli-Sforza L, Dement WC. Genetic factors in canine narcolepsy. Sleep. 1979;1(4):413-21. (Pubitemid 9215714)
64. Ripley B, Fujiki N, Okura M, Mignot E, Nishino S. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis. 2001;8(3):525-34. (Pubitemid 32566142)
65. Kushida CA, Baker TL, Dement WC. Electroencephalographic correlates of cataplectic attacks in narcoleptic canines. Electroencephalogr Clin Neurophysiol. 1985;61:61-70. (Pubitemid 15052801)
66. Lucas EA, Foutz AS, Dement WC, Mitler MM. Sleep cycle organization in narcoleptic and normal dogs. Physiol Behav. 1979;23(4):737-43. (Pubitemid 10207036)
67. Lucas EA, Foutz AS, Mitler MM, Brown D, Dement WC. Multiple sleep latency test in normal and narcoleptic canines. Soc Neurosci Abstr. 1978;6:541.
68. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 1997;52(1):27-78. (Pubitemid 27242520)
69. Mitler MM, Dement WC. Sleep studies on canine narcolepsy: pattern and cycle comparisons between affected and normal dogs. Electroencephalogr Clin Neurophysiol. 1977;43(5):691-9. (Pubitemid 8220176)
70. Dean RR, Kilduff TS, Dement WC, Grumet FC. Narcolepsy without unique MHC class II antigen association: studies in the canine model. Hum Immunol. 1989;25:27-35. (Pubitemid 19110077)
71. Motoyama M, Kilduff TS, Lee BSM, Dement WC, McDevitt HO. Restriction fragment length polymorphism in canine narcolepsy. Immunogenetics. 1989;29:124-6. (Pubitemid 19047305)
72. Karczmar AG, Longo VG, De Carolis S. A pharmacological model of paradoxical sleep: the role of cholinergic and monoaminergic systems. Physiol Behav. 1970;5:175-82.
73. Aldrich MS, Hollingsworth Z, Penney JB. Dopamine-receptor autoradiography of human narcoleptic brain. Neurology. 1992;42:410-5.
74. Aldrich MS, Prokopowicz G, Ockert K, Hollingsworth Z, Penny JB, Albin RL. Neurochemical studies of human narcolepsy: alpha-adrenergic receptor autoradiography of human narcoleptic brain and brainstem. Sleep. 1994;17:598-608. (Pubitemid 24348451)
75. Aldrich MS. The neurobiology of narcolepsy-cataplexy. Prog Neurobiol. 1993;41:533-41.
76. Bowersox S, Kilduff T, Faul K, Dement WC, Ciaranello RD. Brain dopamine receptor levels elevated in canine narcolepsy. Brain Res. 1987;402:44-8. (Pubitemid 17006927)
77. Boehme R, Baker T, Mefford I, Barchas J, Dement WC, Ciaranello R. Narcolepsy: cholinergic receptor changes in an animal model. Life Sci. 1984;34:1825-8. (Pubitemid 14127613)
78. Faull KF, Zeller-DeAmicis LC, Radde L, Bowersox SS, Baker TL, Kilduff TS, et al. Biogenic amine concentrations in the brains of normal and narcoleptic canines: current status. Sleep. 1986;9(1):107-10. (Pubitemid 18008480)
79. Kilduff T, Bowersox SS, Kaitin KI, Baker TL, Ciaranello RD, Dement WC. Muscarinic cholinergic receptors and the canine model of narcolepsy. Sleep. 1986;9:102-7.
80. Mefford IN, Baker TL, Boehme R, Foutz AS, Ciaranello RD, Barchas JD, et al. Narcolepsy: biogenic amine deficits in an animal model. Science. 1983;220:629-32. (Pubitemid 13130152)
81. Miller JD, Faull KF, Bowersox SS, Dement WC. CNS monoamines and their metabolites in canine narcolepsy: a replication study. Brain Res. 1990;509:169-71. (Pubitemid 20043638)
82. Hobson JA, McCarley RW, Wyzinski PW. Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups. Science. 1975;189:55-8.
83. McCarley RW, Hobson JA. Neuronal excitability modulation over the sleep cycle: a structural and mathematical model. Science. 1975;189(4196):58-60.
84. Mignot E, Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement WC. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology. 1993;113(1):76-82. (Pubitemid 23341049)
85. Nishino S, Arrigoni J, Shelton J, Dement WC, Mignot E. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep. 1993;16(8):706-12. (Pubitemid 24054961)
86. Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994;17(5):436-7. (Pubitemid 24271517)
87. Nishino S, Mao J, Sampathkumaran R, Shelton J. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online. 1998;1(1):49-61.
88. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148-54. doi:10.1001/jama.2009.351.
89. Nishino S, Tafti M, Reid MS, Shelton J, Siegel JM, Dement WC, et al. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy. J Neurosci. 1995;15(7 Pt 1):4806-14.
90. Reid MS, Tafti M, Nishino S, Sampathkumaran R, Siegel JM, Dement WC, et al. Local administration of dopaminergic drugs into the ventral tegmental area modulate cataplexy in the narcoleptic canine. Brain Res. 1996;733:83-100. (Pubitemid 26300960)
91. Fernandez-Vina M, Moraes JR, Moraes ME, Miller S, Stasny P. HLA class II haplotypes in Amerindians and in black North and South Americans. Tissue Antigens. 1991;38:235-7.
92. Behar E, Lin X, Grumet FC, Mignot E. A new DRB1*1202 allele (DRB1*12022) found in association with DQA1*0102 and DQB1*0602 in two black narcoleptic subjects. Immunogenetics. 1995;41(1):52. (Pubitemid 24373343)
93. Neely SE, Rosenberg RS, Spire JP, Antel J, Arnason W. Familial narcolepsy and HLA antigens. Ann Neurol. 1986;20(1):168.
94. Mignot E, Lin X, Hesla PE, Dement WC, Guilleminault C, Grumet FC. A novel HLA DR17, DQ1 (DQA1-0102/DQB1-0602 positive) haplotype predisposing to narcolepsy in Caucasians. Sleep. 1993;16(8):764-5. (Pubitemid 24054971)
95. Han F, Lin L, Li J, Dong SX, An P, Zhao L, et al. HLA-DQ association and allele competition in Chinese narcolepsy. Tissue Antigens. 2012;80(4):328-35. doi:10.1111/j.1399-0039.2012.01948.x.
96. Mignot E. Genetic and familial aspects of narcolepsy. Neurology. 1998;50(2 Suppl 1):S16-22. (Pubitemid 28100862)
97. Guilleminault C, Mignot E, Grumet FC. Familial patterns of narcolepsy. Lancet. 1989;2(8676):1376-9. (Pubitemid 20002976)
98. Honda Y, Asaka C, Tanimura M, Furusho T. A genetic study of narcolepsy and excessive daytime sleepiness in 308 families with a narcolepsy or hypersomnia proband. In: Guilleminault C, Lugaresi E, editors. Sleep/wake disorders: natural history, epidemiology and long-term evolution. New York: Raven Press; 1983. p. 187-99.
99. Nevsimalova S, Mignot E, Sonka K, Arrigoni JL. Familial aspects of narcolepsy-cataplexy in the Czech Republic. Sleep. 1997;20(11):1021-6. (Pubitemid 28042451)
100. Mignot E, Wang C, Rattazzi C, Gaiser C, Lovett M, Guilleminault C, et al. Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin heavy-chain switch-like segment. Proc Natl Acad Sci USA. 1991;88(8):3475-8. (Pubitemid 21916644)
101. Mignot E, Bell RA, Rattazzi C, Lovett M, Grumet FC, Dement WC. An immunoglobulin switchlike sequence is linked with canine narcolepsy. Sleep. 1994;17(8 Suppl):S68-76.
102. Li R, Mignot E, Faraco J, Kadotani H, Cantanese J, Zhao B, et al. Construction and characterization of an eightfold redundant dog genomic bacterial artificial chromosome library. Genomics. 1999;58(1):9-17. (Pubitemid 29269874)
103. Li R, Faraco JH, Lin L, Lin X, Hinton L, Rogers W, et al. Physical and radiation hybrid mapping of canine chromosome 12, in a region corresponding to human chromosome 6p12-q12. Genomics. 2001;73(3):299-315. (Pubitemid 32463726)
104. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98(3):365-76. (Pubitemid 29380571)
105. De Lecea L, Kilduff TS, Peyron C, Gao X-B, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95:322-7. (Pubitemid 28103952)
106. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573-85. (Pubitemid 28101119)
107. Gautvik KM, de Lecea L, Gautvik VT, Danielson PE, Tranque P, Dopazo A, et al. Overview of the most prevalent hypothala-mus- specific mRNAs, as identified by directional tag PCR subtraction. Proc Natl Acad Sci USA. 1996;93(16):8733-8. (Pubitemid 26269629)
108. Edwards CM, Abusnana S, Sunter D, Murphy KG, Ghatei MA, Bloom SR. The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin. J Endocrinol. 1999;160(3):R7-12.
109. Haynes AC, Jackson B, Overend P, Buckingham RE, Wilson S, Tadayyon M, et al. Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. Peptides. 1999;20(9):1099-105. (Pubitemid 29424217)
110. Ida T, Nakahara K, Katayama T, Murakami N, Nakazato M. Effect of lateral cerebroventricular injection of the appetitestimulating neuropeptide, orexin and neuropeptide Y, on the various behavioral activities of rats. Brain Res. 1999;821:526-9. (Pubitemid 29222818)
111. Lubkin M, Stricker-Krongrad A. Independent feeding and metabolic actions of orexins in mice. Biochem Biophys Res Commun. 1998;253(2):241-5. (Pubitemid 29026688)
112. Yamanaka A, Sakurai T, Katsumoto T, Yanagisawa M, Goto K. Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res. 1999;849(1-2):248-52.
113. Girault EM, Yi CX, Fliers E, Kalsbeek A. Orexins, feeding, and energy balance. Prog Brain Res. 2012;198:47-64. doi:10.1016/B978-0-444-59489-1.00005-7.
114. Rolls A, Schaich Borg J, de Lecea L. Sleep and metabolism: role of hypothalamic neuronal circuitry. Best Pract Res Clin Endocrinol Metab. 2010;24(5):817-28. doi:10.1016/j.beem.2010.08.002.
115. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18(23):9996-10015. (Pubitemid 28543775)
116. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K. Distribution of orexin neurons in the adult rat brain. Brain Res. 1999;827:243-60. (Pubitemid 29222929)
117. Horvath TL, Peyron C, Diano S, Ivanov A, Aston-Jones G, Kilduff TS, et al. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J Comp Neurol. 1999;415(2):145-59. (Pubitemid 29519873)
118. Brown RE, Sergeeva O, Eriksson KS, Haas HL. Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology. 2001;40(3):457-9. (Pubitemid 32144724)
119. Eriksson KS, Sergeeva O, Brown RE, Haas HL. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci. 2001;21(23):9273-9. (Pubitemid 33096871)
120. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98(4):437-51. (Pubitemid 29402482)
121. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6(9):991-7.
122. Nevsimalova S, Vankova J, Sonka K, Faraco J, Rogers W, Overeem S, et al. Hypocretin (orexin) deficiency in narcolepsy-cataplexy. Sb Lek. 2000;101(4):381-6.
123. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355(9197):39-40. (Pubitemid 30072183)
124. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27(3):469-74.
125. Blouin AM, Thannickal TC, Worley PF, Baraban JM, Reti IM, Siegel JM. Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology. 2005;65(8):1189-92. doi:10.1212/01.wnl.0000175219.01544.c8. (Pubitemid 41508209)
126. Crocker A, Espana RA, Papadopoulou M, Saper CB, Faraco J, Sakurai T et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology. 2005;65(8):1184-8. (Pubitemid 41508208)
127. Valko PO, Gavrilov YV, Yamamoto M, Reddy H, Haybaeck J, Mignot E, et al. Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann Neurol. 2013;74(6):794-804. doi:10.1002/ana.24019.
128. John J, Thannickal TC, McGregor R, Ramanathan L, Ohtsu H, Nishino S, et al. Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. Ann Neurol. 2013;74(6):786-93. doi:10.1002/ana.23968.
129. Tanaka S, Honda Y, Inoue Y, Honda M. Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. Sleep. 2006;29(5):633-8.
130. Black JL 3rd, Silber MH, Krahn LE, Fredrickson PA, Pankratz VS, Avula R, et al. Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. Sleep. 2005;28(4):427-31. (Pubitemid 40489837)
131. Black JL 3rd, Silber MH, Krahn LE, Avula RK, Walker DL, Pankratz VS, et al. Studies of humoral immunity to preprohypocretin in human leukocyte antigen DQB1*0602-positive narcoleptic subjects with cataplexy. Biol Psychiatry. 2005;58(6):504-9. doi:10.1016/j.biopsych.2005.04.026. (Pubitemid 41393613)
132. Martinez-Rodriguez JE, Sabater L, Graus F, Iranzo A, Santamaria J. Evaluation of hypothalamic-specific autoimmunity in patients with narcolepsy. Sleep. 2007;30(1):27-8. (Pubitemid 46098866)
133. Knudsen S, Mikkelsen JD, Jennum P. Antibodies in narcolepsy-cataplexy patient serum bind to rat hypocretin neurons. Neuro- Report. 2007;18(1):77-9. doi:10.1097/WNR.0b013e328010baad. (Pubitemid 46188214)
134. Overeem S, Verschuuren JJ, Fronczek R, Schreurs L, den Hertog H, Hegeman-Kleinn IM, et al. Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy. J Neuroimmunol. 2006;174(1-2):187-91. doi:10.1016/j.jneuroim.2006.02.010.
135. Overeem S, Black JL 3rd, Lammers GJ. Narcolepsy: immunological aspects. Sleep Med Rev. 2008;12(2):95-107. doi:10.1016/j.smrv.2007.07.010.
136. Smith AJ, Jackson MW, Neufing P, McEvoy RD, Gordon TP. A functional autoantibody in narcolepsy. Lancet. 2004;364(9451):2122-4. doi:10.1016/S0140- 6736(04)17553-3. (Pubitemid 39626808)
137. Katzav A, Arango MT, Kivity S, Tanaka S, Givaty G, Agmon-Levin N, et al. Passive transfer of narcolepsy: anti-TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice. J Autoimmun. 2013;45:24-30. doi:10.1016/j.jaut.2013.06.010.
138. Jackson MW, Reed JH, Smith AJ, Gordon TP. An autoantibody in narcolepsy disrupts colonic migrating motor complexes. J Neurosci. 2008;28(49):13303-9. doi:10.1523/JNEUROSCI.4489-08.2008.
139. Cvetkovic-Lopes V, Bayer L, Dorsaz S, Maret S, Pradervand S, Dauvilliers Y, et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest. 2010;120(3):713-9. doi:10.1172/JCI41366.
140. Dougherty JD, Schmidt EF, Nakajima M, Heintz N. Analytical approaches to RNA profiling data for the identification of genes enriched in specific cells. Nucleic Acids Res. 2010;38(13):4218-30. doi:10.1093/nar/gkq130.
141. Honda M, Eriksson KS, Zhang S, Tanaka S, Lin L, Salehi A, et al. IGFBP3 colocalizes with and regulates hypocretin (orexin). PLoS ONE. 2009;4(1):e4254. doi:10.1371/journal.pone.0004254.
142. Eriksson KS, Mignot E. T-box 3 is expressed in the adult mouse hypothalamus and medulla. Brain Res. 2009;1302:233-9. doi:10.1016/j.brainres. 2009.08.101.
143. DauvilliersY,Montplaisir J, Cochen V, Desautels A, Einen M, Lin L, et al. Post-H1N1 narcolepsy-cataplexy. Sleep. 2010;33(11):1428-30.
144. Lind A, Ramelius A, Olsson T, Arnheim-Dahlstrom L, Lamb F, Khademi M et al. A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009-2010. J Autoimmun. 2014. doi:10.1016/j.jaut.2014.01.031.
145. Pelin Z, Guilleminault C, Risch N, Grumet FC, Mignot E. HLA-DQB1* 0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group. Tissue Antigens. 1998;51(1):96-100. (Pubitemid 28014550)
146. Mignot E, Lin L, Rogers W, Honda Y, Qiu X, Lin X, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy- cataplexy in three ethnic groups. Am J Hum Genet. 2001;68(3):686-99. (Pubitemid 32202763)
147. Hong SC, Lin L, Lo B, Jeong JH, Shin YK, Kim SY, et al. DQB1*0301 and DQB1*0601 modulate narcolepsy susceptibility in Koreans. Hum Immunol. 2007;68(1):59-68. doi:10.1016/j.humimm.2006.10.006. (Pubitemid 46026883)
148. Weiner Lachmi K, Lin L, Kornum BR, Rico T, Lo B, Aran A, et al. DQB1&z.ast;06:02 allele-specific expression varies by allelic dosage, not narcolepsy status. Hum Immunol. 2012;73(4):405-10. doi:10.1016/j.humimm.2012.01. 004.
149. Mignot E, Lin L, Li H, Thomson G, Lathrop M, Thorsby E et al. 13th International Histocompatibility Working group for narcolepsy joint report. In: Hansen J, Dupont B, editors. Immunobiology of human MHC. Proceedings of the 13th International Histocompatibility Workshop and Congress (Seattle, WA 2004). Seattle: IHWG Press; 2006. p. 782-7.
150. Hohjoh H, Terada N, Honda Y, Juji T, Tokunaga K. Negative association of the HLA-DRB1*1502-DQB1*0601 haplotype with human narcolepsy. Immunogenetics. 2001;52(3-4):299-301. (Pubitemid 32142819)
151. Hor H, Kutalik Z, Dauvilliers Y, Valsesia A, Lammers GJ, Donjacour CE, et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet. 2010;42(9):786-9. doi:10.1038/ng.647.
152. Tafti M, Hor H, Dauvilliers Y, Lammers GJ, Overeem S, Mayer G, et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep. 2014;37(1):19-25. doi:10.5665/sleep.3300.
153. Ollila HM, Fernandes-Vina M, Mignot E. Alelle competition in narcolepsy. Sleep. 2014;in press.
154. Hallmayer J, Faraco J, Lin L, Hesselson S, Winkelmann J, Kawashima M, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet. 2009;41(6):708-11. doi:10.1038/ng.372.
155. Faraco J, Lin L, Kornum BR, Kenny EE, Trynka G, Einen M, et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet. 2013;9(2):e1003270. doi:10.1371/journal.pgen.1003270.
156. Kornum BR, Kawashima M, Faraco J, Lin L, Rico T, Hesselson S et al. Common variants in P2RY11 are associated with narcolepsy. Nat Genet. 2011;43(1).
157. Han F, Faraco J, Dong XS, Ollila HM, Lin L, Li J. Genome wide analysis of narcolepsy in china implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemic. PLoS Genet. 2013;9(10):e1003880-e. doi:10.1371/journal.pgen.1003880.
158. Manku H, Langefeld CD, Guerra SG, Malik TH, Alarcon-Riquelme M, Anaya JM, et al. Trans-ancestral studies fine map the SLE-susceptibility locus TNFSF4. PLoS Genet. 2013;9(7):e1003554. doi:10.1371/journal.pgen.1003554.
159. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, HuiK Y, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119-24. doi:10.1038/nature11582.
160. Kim K, Bang SY, Lee HS, Cho SK, Choi CB, Sung YK, et al. High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. Ann Rheum Dis. 2014;. doi:10.1136/annrheumdis- 2013-204749.
161. Cooper JD, Smyth DJ, Smiles AM, Plagnol V, Walker NM, Allen JE, et al. Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet. 2008;40(12):1399-401. doi:10.1038/ng.249.
162. Hirota T, Takahashi A, Kubo M, Tsunoda T, Tomita K, Sakashita M, et al. Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. Nat Genet. 2012;44(11):1222-6. doi:10.1038/ng.2438.
163. Moran CJ, Walters TD, Guo CH, Kugathasan S, Klein C, Turner D, et al. IL-10R polymorphisms are associated with very-earlyonset ulcerative colitis. Inflamm Bowel Dis. 2013;19(1):115-23. doi:10.1002/ibd.22974.
164. Winkelmann J, Lin L, Schormair B, Kornum BR, Faraco J, Plazzi G, et al. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and
165. Han F, Schormair B, Pizza F, Ollila HM, Nevsimalova S, Jennum P et al. HLA DQB1&z.ast;06:02 negative narcolepsy with hypocretin/orexin deficiency. Sleep. 2014;in press.
166. Hecht M, Lin L, Kushida CA, Umetsu DT, Taheri S, Einen M, et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep. 2003;26(7):809-10. (Pubitemid 39610624)
167. Snider LA, Swedo SE. PANDAS: current status and directions for research. Mol Psychiatry. 2004;9(10):900-7. doi:10.1038/sj.mp.4001542. (Pubitemid 39381954)
168. Cardoso F. Sydenham's chorea. Handb Clin Neurol. 2011;100:221-9. doi:10.1016/B978-0-444-52014-2.00014-8.
169. Billiard M, Laaberki M, Reygrobellet C, Seignalet J, Brissaud L, Besset A. Elevated antibodies to streptococcal antigens in narcoleptic subjects. Sleep Res. 1989;201.
170. Montplaisir J, Poirer G, Lapierre O, Montplaisir S. Streptococcal antibodies in narcolepsy and idiopathic hypersomnia. Sleep Res. 1989;18:271.
171. Mueller-Eckhardt G, Meier-Ewart K, Schiefer HG. Is there an infectious origin of narcolepsy? Lancet. 1990;335(8686):424. (Pubitemid 20059416)
172. Dale RC, Church AJ, Surtees RA, Lees AJ, Adcock JE, Harding B, et al. Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain. 2004;127(Pt 1):21-33. doi:10.1093/brain/awh008. (Pubitemid 38055343)
173. Aran A, Weiner K, Lin L, Finn LA, Greco MA, Peppard P, et al. Post-streptococcal auto-antibodies inhibit protein disulfide isomerase and are associated with insulin resistance. PLoS ONE. 2010;5(9):e12875. doi:10.1371/journal.pone.0012875.
174. Aran A, Lin L, Nevsimalova S, Plazzi G, Hong SC, Weiner K, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009;32(8):979-83.
175. Koepsell TD, Longstreth WT, Ton TG. Medical exposures in youth and the frequency of narcolepsy with cataplexy: a popu-lation- based case-control study in genetically predisposed people. J Sleep Res. 2009;19(1 Pt 1):80-6. doi:10.1111/j.1365-2869.2009.00756.x.
176. Aran A, Lin L, Finn LA, Weiner K, Peppard P, Young T, et al. Post-streptococcal antibodies are associated with metabolic syndrome in a population-based cohort. PLoS ONE. 2011;6(9):e25017. doi:10.1371/journal.pone. 0025017.
177. Han F, Lin L, Li J, Aran A, Dong SX, An P, et al. Presentations of primary hypersomnia in Chinese children. Sleep. 2011;34(5):627-32.
178. Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol. 2011;70(3):410-7. doi:10.1002/ana.22587.
179. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science. 2009;324(5934):1557-61. doi:10.1126/science.1176062.
180. Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine. 2010;28(31):4895-902. doi:10.1016/j.vaccine. 2010.05.031.
181. Broadbent AJ, Subbarao K. Influenza virus vaccines: lessons from the 2009 H1N1 pandemic. Curr Opin Virol. 2011;1(4):254-62. doi:10.1016/j.coviro.2011.08. 002.
182. Belongia EA, Irving SA, Waring SC, Coleman LA, Meece JK, Vandermause M, et al. Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. JAMA. 2010;304(10):1091-8. doi:10.1001/jama.2010.1277.
183. Viboud C, Simonsen L. Global mortality of 2009 pandemic influenza A H1N1. Lancet Infect Dis. 2012;12(9):651-3. doi:10.1016/S1473-3099(12)70152-4.
184. Han F, Lin L, Li J, Dong XS, Mignot E. Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic. Ann Neurol. 2012. doi:10.1002/ana.23799.
185. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE. 2012;7(3):e33536. doi:10.1371/journal.pone.0033536.
186. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, Hublin C, Linna M, Olsen P, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE. 2012;7(3):e33723. doi:10.1371/journal.pone.0033723.
187. Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ. 2011;343:d5956. doi:10.1136/bmj.d5956.
188. Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology. 2013;80(14):1315-21. doi:10.1212/WNL.0b013e31828ab26f.
189. Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, Feltelius N. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med. 2014;275(2):172-90. doi:10.1111/joim.12150.
190. Heier MS, Gautvik KM, Wannag E, Bronder KH, Midtlyng E, Kamaleri Y, et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med. 2013;14(9):867-71. doi:10.1016/j.sleep.2013.03.020.
191. Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, Shneerson J, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ. 2013;346:f794. doi:10.1136/bmj.f794.
192. Dauvilliers Y, Arnulf I, Lecendreux M, Monaca Charley C, Franco P, Drouot X, et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain. 2013;36(Pt 8):2486-96. doi:10.1093/brain/ awt187.
193. Barker CI, Snape MD. Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis. 2014;14(3):227-38. doi:10.1016/S1473-3099(13)70238-X.
194. Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, Hviid A, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine. 2013;31(8):1246-54. doi:10.1016/j. vaccine.2012.12.015.
195. Ahmed SS, Schur PH, Macdonald NE, Steinman L. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun. 2014. doi:10.1016/j.jaut.2014.01.033.
196. Moris P, van der Most R, Leroux-Roels I, Clement F, Drame M, Hanon E, et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol. 2011;31(3):443-54. doi:10.1007/s10875-010-9490-6.
197. Montplaisir J, Petit D, Quinn MJ, Ouakki M, Deceuninck G, Desautels A, Mignot E, De Wals P. Risque de narcolepsie associée au vaccin influenza pandémique adjuvanté 2009 au Québec. Congrè s de l'Association des épidémiologistes de langue française et de la Société française de santé publique, Bordeaux, 17-19 octobre 2013.
198. De la Herran-Arita AK, Kornum BR, Mahlios J, Jiang W, Lin L, Hou T, et al. CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1influenzaAepitope in narcolepsy. Sci Transl Med. 2013;5(216):216ra176. doi:10.1126/scitranslmed.3007762.
199. Siebold C, Hansen BE, Wyer JR, Harlos K, Esnouf RE, Svejgaard A, et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc Natl Acad Sci USA. 2004;101(7):1999-2004. doi:10.1073/pnas.0308458100. (Pubitemid 38229004)
200. Heifetz A, Barker O, Morris GB, Law RJ, Slack M, Biggin PC. Toward an understanding of agonist binding to human orexin-1 and orexin-2 receptors with G-protein-coupled receptor modeling and site-directed mutagenesis. Biochemistry. 2013;52(46):8246-60. doi:10.1021/bi401119m.
201. Gough SC, Simmonds MJ. The HLA region and autoimmune disease: associations and mechanisms of action. Curr Genomics. 2007;8(7):453-65. doi:10.2174/138920207783591690. (Pubitemid 351486276)
202. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol. 2012;72(1):53-64. doi:10.1002/ana.23651.
203. Denman AM, Rager-Zisman B. Viruses and autoimmune diseases adapting Koch's postulates. Autoimmun Rev. 2004;3(5):355-61. doi:10.1016/j.autrev.2004. 03.001. (Pubitemid 38993356)
204. Han F, Faraco J, Dong X, Ollila H, Lin L, Li J et al. Genome wide analysis of narcolepsy in China implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemic. PLoS Genet. 2013;9(10):e1003880. doi:10.1371/journal.pgen.1003880.
205. Chaloupka I, Schuler A, Marschall M, Meier-Ewert H. Comparative analysis of six european influenza vaccines. Eur J Clin Microbiol Infect Dis. 1996;15:121-7. (Pubitemid 26098745)
206. Jean C, Louie JK, Glaser CA, Harriman K, Hacker JK, Aranki F, et al. Invasive group A streptococcal infection concurrent with 2009 H1N1 influenza. Clin Infect Dis. 2010;50(10):e59-62. doi:10.1086/652291.
207. ECDC. European Centre for Disease Prevention and Control: Narcolepsy in association with pandemic influenza vaccination (a multi-country European epidemiological investigation). Stockholm, Sept 2012. ISBN:978-92-9193-388-4.
208. Melen K, Partinen M, Tynell J, Sillanpaa M, Himanen SL, Saarenpaa-Heikkila O, et al. No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland. PLoS ONE. 2013;8(8):e68402. doi:10.1371/journal. pone.0068402.
209. Dauvilliers Y, Abril B, Mas E, Michel F, Tafti M. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology. 2009;73(16):1333-4. doi:10.1212/WNL. 0b013e3181bd1344.
210. Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol. 2004;56(6):905-8. doi:10.1002/ana.20339. (Pubitemid 39578460)
211. Knudsen S, Biering-Sorensen B, Kornum BR, Petersen ER, Ibsen JD, Gammeltoft S, et al. Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiency. Neurology. 2012;79(1):102-3. doi:10.1212/WNL.0b013e31825dce03.
212. Plazzi G, Poli F, Franceschini C, Parmeggiani A, Pirazzoli P, Bernardi F, et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol. 2008;255(10):1549-54. doi:10.1007/s00415- 008-0983-7.
213. Valko PO, Khatami R, Baumann CR, Bassetti CL. No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J Neurol. 2008;255(12):1900-3. doi:10.1007/s00415-008-0996-2.
214. Fronczek R, Verschuuren J, Lammers GJ. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol. 2007;254(11):1607-8. doi:10. 1007/s00415-007-0594-8.
215. Löwenfeld L. Uber Narkolepsie. Munch Med Wochenschr. 1902;49:1041-5.
216. Prinzmetal M, Bloomberg W. The use of benzedrine for the treatment of narcolepsy. J Am Med Assoc. 1935;105:2051-4.
217. Knecht CD, Oliver JE, Redding R, Selcer R, Johnson G. Narcolepsy in a dog and a cat. J Am Vet Med Assoc. 1973;162(12):1052-3.
218. Honda Y, Asake A, Tanaka Y, Juji T. Discrimination of narcolepsy by using genetic markers and HLA. Sleep Res. 1983;12:154.